Metyrapone Treatment in Endogenous Cushing’s Syndrome: Results at Week 12 From PROMPT, a Prospective International Multicenter, Open-Label, Phase III/IV Study

Background: Metyrapone is a steroidogenesis inhibitor approved in Europe for the treatment of endogenous Cushing’s syndrome (CS) based on observational retrospective studies published over more than 50 years. We present data from the first prospective study designed to confirm metyrapone efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Nieman, Lynnette K, Boscaro, Marco, Scaroni, Carla Maria, Deutschbein, Timo, Mezosi, Emese, Driessens, Natacha, Georgescu, Carmen Emanuela, Hubalewska-D, Alicja, Berker, Dilek, Jarzab, Barbara Maria, Maiter, Dominique M, Reincke, Martin, Loli, Paola, Zampetti, Benedetta, Atmaca, Ayşegül, Badiu, Corin P, Beckers, Albert M, Bolanowski, Marek, Cavagnini, Francesco, Unger, Nicole, Giordano, Roberta, Hanzu, Felicia Alexandra, Terzolo, Massimo, Bostnavaron, Martine, Toth, Miklos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090655/
http://dx.doi.org/10.1210/jendso/bvab048.1053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090655/
http://dx.doi.org/10.1210/jendso/bvab048.1053

Ejemplares similares